RENOWN HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1862-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.renown.org/
Helix Unveils Model Predicting Semaglutide Weight Loss Response
• Helix presented a precision effectiveness model at ASHG 2024 predicting 12-month weight loss from semaglutide in diverse populations.
• The model uses a polygenic risk score and co-morbid factors like type 2 diabetes and hypertension to predict individual responses.
• Patients in the top quintile of the score were approximately twice as likely to achieve 10% weight loss compared to the bottom quintile.
• The model aims to improve treatment decisions by estimating weight loss expectations and guiding dosage considerations for semaglutide.
© Copyright 2025. All Rights Reserved by MedPath